These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28646226)

  • 1. A microRNA signature of response to erlotinib is descriptive of TGFβ behaviour in NSCLC.
    Krentz Gober M; Collard JP; Thompson K; Black EP
    Sci Rep; 2017 Jun; 7(1):4202. PubMed ID: 28646226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
    Wang T; Wang D; Zhang L; Yang P; Wang J; Liu Q; Yan F; Lin F
    J Exp Clin Cancer Res; 2019 May; 38(1):226. PubMed ID: 31138318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor.
    Zhao FY; Han J; Chen XW; Wang J; Wang XD; Sun JG; Chen ZT
    Int J Mol Med; 2016 Jul; 38(1):183-91. PubMed ID: 27177336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs.
    Farhan M; Malik A; Ullah MF; Afaq S; Faisal M; Farooqi AA; Biersack B; Schobert R; Ahmad A
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
    Soucheray M; Capelletti M; Pulido I; Kuang Y; Paweletz CP; Becker JH; Kikuchi E; Xu C; Patel TB; Al-Shahrour F; Carretero J; Wong KK; Jänne PA; Shapiro GI; Shimamura T
    Cancer Res; 2015 Oct; 75(20):4372-83. PubMed ID: 26282169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway.
    Han Z; Zhou X; Li S; Qin Y; Chen Y; Liu H
    Oncol Rep; 2017 Nov; 38(5):3064-3070. PubMed ID: 28901474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
    Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
    J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RP11-874 J12.4 promotes erlotinib resistance in non-small cell lung cancer via increasing AXL expression.
    Huang S; Zhang J; Wu X; Liang B; Pang N; Yang L; Zhang Z
    Life Sci; 2024 Aug; 351():122849. PubMed ID: 38897346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
    Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
    PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors.
    Izumchenko E; Chang X; Michailidi C; Kagohara L; Ravi R; Paz K; Brait M; Hoque MO; Ling S; Bedi A; Sidransky D
    Cancer Res; 2014 Jul; 74(14):3995-4005. PubMed ID: 24830724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway.
    Han J; Zhao F; Zhang J; Zhu H; Ma H; Li X; Peng L; Sun J; Chen Z
    Int J Oncol; 2016 May; 48(5):1855-67. PubMed ID: 26936292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
    Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y
    Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
    Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
    Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib.
    Amri J; Molaee N; Baazm M; Karami H
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2781-2787. PubMed ID: 31554377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.
    Liao J; Lin J; Lin D; Zou C; Kurata J; Lin R; He Z; Su Y
    Sci Rep; 2017 Apr; 7(1):781. PubMed ID: 28396596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-145 and miR-203 represses TGF-β-induced epithelial-mesenchymal transition and invasion by inhibiting SMAD3 in non-small cell lung cancer cells.
    Hu H; Xu Z; Li C; Xu C; Lei Z; Zhang HT; Zhao J
    Lung Cancer; 2016 Jul; 97():87-94. PubMed ID: 27237033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early emergence of de novo EGFR T790M gatekeeper mutations during erlotinib treatment in PC9 non-small cell lung cancer cells.
    Kim S; Park AK; Cho J
    Biochem Biophys Res Commun; 2018 Sep; 503(2):710-714. PubMed ID: 29909007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells.
    Hussmann D; Madsen AT; Jakobsen KR; Luo Y; Sorensen BS; Nielsen AL
    Oncotarget; 2017 May; 8(20):33300-33315. PubMed ID: 28418902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients.
    Bisagni A; Pagano M; Maramotti S; Zanelli F; Bonacini M; Tagliavini E; Braglia L; Paci M; Mozzarelli A; Croci S
    PLoS One; 2018; 13(4):e0196350. PubMed ID: 29689091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.